263 related articles for article (PubMed ID: 31631027)
1. ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures.
Qadeer ZA; Valle-Garcia D; Hasson D; Sun Z; Cook A; Nguyen C; Soriano A; Ma A; Griffiths LM; Zeineldin M; Filipescu D; Jubierre L; Chowdhury A; Deevy O; Chen X; Finkelstein DB; Bahrami A; Stewart E; Federico S; Gallego S; Dekio F; Fowkes M; Meni D; Maris JM; Weiss WA; Roberts SS; Cheung NV; Jin J; Segura MF; Dyer MA; Bernstein E
Cancer Cell; 2019 Nov; 36(5):512-527.e9. PubMed ID: 31631027
[TBL] [Abstract][Full Text] [Related]
2. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
Li Z; Takenobu H; Setyawati AN; Akita N; Haruta M; Satoh S; Shinno Y; Chikaraishi K; Mukae K; Akter J; Sugino RP; Nakazawa A; Nakagawara A; Aburatani H; Ohira M; Kamijo T
Oncogene; 2018 May; 37(20):2714-2727. PubMed ID: 29507419
[TBL] [Abstract][Full Text] [Related]
3. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
4. ATRX binds to atypical chromatin domains at the 3' exons of zinc finger genes to preserve H3K9me3 enrichment.
Valle-García D; Qadeer ZA; McHugh DS; Ghiraldini FG; Chowdhury AH; Hasson D; Dyer MA; Recillas-Targa F; Bernstein E
Epigenetics; 2016 Jun; 11(6):398-414. PubMed ID: 27029610
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
George SL; Lorenzi F; King D; Hartlieb S; Campbell J; Pemberton H; Toprak UH; Barker K; Tall J; da Costa BM; van den Boogaard ML; Dolman MEM; Molenaar JJ; Bryant HE; Westermann F; Lord CJ; Chesler L
EBioMedicine; 2020 Sep; 59():102971. PubMed ID: 32846370
[TBL] [Abstract][Full Text] [Related]
6. Disruption of ATRX-RNA interactions uncovers roles in ATRX localization and PRC2 function.
Ren W; Medeiros N; Warneford-Thomson R; Wulfridge P; Yan Q; Bian J; Sidoli S; Garcia BA; Skordalakes E; Joyce E; Bonasio R; Sarma K
Nat Commun; 2020 May; 11(1):2219. PubMed ID: 32376827
[TBL] [Abstract][Full Text] [Related]
7. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.
van Gerven MR; Bozsaky E; Matser YAH; Vosseberg J; Taschner-Mandl S; Koster J; Tytgat GAM; Molenaar JJ; van den Boogaard M
Cancer Sci; 2022 Jun; 113(6):2167-2178. PubMed ID: 35384159
[TBL] [Abstract][Full Text] [Related]
8. ATRX guards against aberrant differentiation in mesenchymal progenitor cells.
Fang Y; Barrows D; Dabas Y; Carroll TS; Singer S; Tap WD; Nacev BA
Nucleic Acids Res; 2024 May; 52(9):4950-4968. PubMed ID: 38477352
[TBL] [Abstract][Full Text] [Related]
9. Global changes in chromatin accessibility and transcription following ATRX inactivation in human cancer cells.
Liang J; Liu H; Li G; Qian J; Gao R; Zhou Y; Wang X
FEBS Lett; 2020 Jan; 594(1):67-78. PubMed ID: 31329278
[TBL] [Abstract][Full Text] [Related]
10. Stalled replication forks within heterochromatin require ATRX for protection.
Huh MS; Ivanochko D; Hashem LE; Curtin M; Delorme M; Goodall E; Yan K; Picketts DJ
Cell Death Dis; 2016 May; 7(5):e2220. PubMed ID: 27171262
[TBL] [Abstract][Full Text] [Related]
11. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
[TBL] [Abstract][Full Text] [Related]
12. Two opposing gene expression patterns within ATRX aberrant neuroblastoma.
van Gerven MR; Schild L; van Arkel J; Koopmans B; Broeils LA; Meijs LAM; van Oosterhout R; van Noesel MM; Koster J; van Hooff SR; Molenaar JJ; van den Boogaard ML
PLoS One; 2023; 18(8):e0289084. PubMed ID: 37540673
[TBL] [Abstract][Full Text] [Related]
13. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
14. Retinal interneuron survival requires non-cell-autonomous Atrx activity.
Lagali PS; Medina CF; Zhao BY; Yan K; Baker AN; Coupland SG; Tsilfidis C; Wallace VA; Picketts DJ
Hum Mol Genet; 2016 Nov; 25(21):4787-4803. PubMed ID: 28173139
[TBL] [Abstract][Full Text] [Related]
15. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract][Full Text] [Related]
17. TSPYL2 Regulates the Expression of EZH2 Target Genes in Neurons.
Liu H; Peng L; So J; Tsang KH; Chong CH; Mak PHS; Chan KM; Chan SY
Mol Neurobiol; 2019 Apr; 56(4):2640-2652. PubMed ID: 30051352
[TBL] [Abstract][Full Text] [Related]
18. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
19. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
20. ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease.
Lee J; Hong YK; Jeon GS; Hwang YJ; Kim KY; Seong KH; Jung MK; Picketts DJ; Kowall NW; Cho KS; Ryu H
Cell Death Differ; 2012 Jul; 19(7):1109-16. PubMed ID: 22240898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
